Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript May 11, 2026
Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.6, expectations were $1.54.
Operator: At this time, I would like to welcome everyone to Halozyme’s First Quarter 2026 Financial and Operating Results Conference Call. Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme’s Vice President of Investor Relations and Corporate Communications....
